Media
Press Releases
November 14, 2025
Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™
November 13, 2025
Lupin Establishes a New Global Standard in Sustainable Pharma with an S&P Global ESG Score of 91
November 12, 2025
Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility
November 8, 2025
Lupin Bioresearch Center Receives Zero Observations from U.S. FDA After Successful Inspection and Assessment
November 5, 2025
Lupin Receives EIR from U.S. FDA for its Pithampur Unit-3 Facility
October 28, 2025
Governor Murphy and Local Leaders Attend Ribbon-Cutting Ceremony, Marking the Inauguration of Lupin’s New Corporate Offices in Bridgewater
October 24, 2025
Lupin Launches Authorized Generic Version of Ravicti® in the United States
October 13, 2025
Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
October 3, 2025
Lupin Launches Liraglutide Injection in the United States
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
CloseSearch Product